CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
March 22, 2023 19:23 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics to Present at Upcoming March Investor Conferences
February 28, 2023 16:05 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
January 26, 2023 07:00 ET
|
CytomX Therapeutics Inc.
-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights...
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
January 17, 2023 16:05 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities
January 05, 2023 16:05 ET
|
CytomX Therapeutics Inc.
- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to...
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 05, 2023 16:05 ET
|
CytomX Therapeutics Inc.
Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million...
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
December 22, 2022 17:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 17:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium
December 07, 2022 16:30 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
November 17, 2022 07:00 ET
|
CytomX Therapeutics Inc.
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30...